Fri Sep 20 13:44:14 UTC 2024: ## Zimmer Biomet Holdings Sees Increased Interest from Institutional Investors

**New York, NY (September 20, 2024)** – Zimmer Biomet Holdings, Inc. (NYSE: ZBH), a leading medical technology company, saw significant interest from institutional investors in the second quarter of 2024. Several prominent investment firms, including Edgestream Partners L.P., Price T Rowe Associates Inc. MD, American Century Companies Inc., Primecap Management Co. CA, and Victory Capital Management Inc., increased their holdings in the company.

Edgestream Partners L.P. acquired a new stake in Zimmer Biomet, purchasing 15,420 shares valued at approximately $1,674,000. Meanwhile, Price T Rowe Associates Inc. MD boosted its position by 12.9% in the first quarter, now holding over 10 million shares valued at $1.4 billion. American Century Companies Inc. followed suit, increasing its holdings by 12.6% in the second quarter, currently holding over 6 million shares worth $701 million.

Other notable investors include Primecap Management Co. CA and Victory Capital Management Inc., which grew their stakes by 10.5% and 6.7% respectively during the second quarter.

The surge in institutional investment comes amidst positive developments for Zimmer Biomet. The company exceeded analysts’ expectations in its recent earnings report, posting $2.01 earnings per share for the second quarter, surpassing the projected $1.99. Revenue also met expectations at $1.94 billion, reflecting a 3.9% year-over-year increase.

Analysts remain cautiously optimistic about Zimmer Biomet’s future performance. While some research firms like The Goldman Sachs Group and Barclays have issued “neutral” and “underweight” ratings respectively, others like Oppenheimer and Evercore ISI maintain more bullish stances, projecting “outperform” and “in-line” ratings. The stock currently has a consensus rating of “Hold” with an average target price of $125.17, according to MarketBeat.

Despite the varied analyst opinions, Zimmer Biomet continues to attract investor interest. The company’s strong financial performance, coupled with a growing presence in the medical technology sector, seems to be driving this interest.

**Disclaimer**: This article is intended for informational purposes only and does not constitute financial advice.

Read More